STARTUPS

Ansa Biotechnologies, Inc, a Berkeley, CA-based startup, is developing a technique to control additions of a polymerase that use TdT for de novo DNA synthesis. The ability to synthesize “gene-length” DNA molecules (>500 bases) is invaluable for biological and biomedical research and is a key enabling technology for the rapidly growing field of synthetic biology. … Read more

Protein synthesizers speed up the production of enzymes, therapeutics and lab reagents. Toronto-based Liberumbio’s product use proprietary molecular and hardware technology, enabling biological manufacturer to bring speed, scalability and to reduce cost to protein synthesis. The market size of recombinant proteins today is $119 billion. But it’s expected to reach $400 billion just by 2025. … Read more

IndieBio announced its new batches of startups in June. The life sciences startup incubator allocates each team $250,000 in seed funding plus lab and co-working space and dedicated mentorship. Afterwards, each company becomes part of a network of IndieBio alumni, investors, and biotech entrepreneurs. This is New York’s first batch, and San Francisco’s tenth. Though … Read more

Eligo Bioscience, is a Paris-based next-generation microbiome precision medicine company Eligo Bioscience is pioneering the development of phage-derived DNA delivery vectors for microbial species involved in a number of diseases areas, including infectious diseases, inflammatory diseases and auto-immune diseases. Eligo Bioscience’s EligobioticsTM Plaform EligobioticsTM platform enables the production of DNA delivery vectors derived from phage-like … Read more

According to McKinsey Global Institute (MGI), several trends in science and technology are powering human understanding of biological processes and enabling us to engineer them for myriad uses. MGI says that innovations cover a wide range of interdisciplinary fields in four key arenas: biomolecules, biosystems, biomachine interfaces, and biocomputing. Major breakthroughs in each are reinforcing … Read more

Sana Biotechnology, Inc. (Sana), focused on engineering cells as medicines for patients, announced today the funding of all tranches of its initial financing, raising over $700 million.  Sana’s shareholders include ARCH Venture Partners, Flagship Pioneering, Canada Pension Plan Investment Board, Baillie Gifford, F-Prime Capital, Alaska Permanent Fund, the Public Sector Pension Investment Board, Bezos Expeditions, GV, … Read more